Wadia et al. [62] were the first to use the influenza hemagglutinin-derived fusogenic peptide HA2 in combination with a CPP. Delivery of a Tat-HA2 conjugate with increasing concentrations of a Tat-Cre conjugate enhanced reporter protein activity, presumably through an increased release from macropinosomes. The same fusogenic peptide, linked to a polyarginine-p53 conjugate, promoted release of p53 from macropinosomes and subsequent translocation to the nucleus, accompanied by an enhanced anti-cancer effect [200] .